NCT05359887

Brief Summary

Bariatric surgery (BS) is currently the most effective treatment in severe obesity. However, a considerable percentage of patients undergoing BS fail to lose sufficient weight or regain weight after initial weight loss during long-term follow-up, which may be attributed to personality traits and pathological eating behaviour. Previous positron emission tomography (PET) studies have shown reduced dopamine D2 receptor availability in obese patients and upregulation of this availability following successful BS in the brain's reward system. Dopamine D2 receptor availability in patients with unsuccessful BS has not been investigated to date.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable obesity

Timeline
8mo left

Started Dec 2022

Longer than P75 for not_applicable obesity

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress85%
Dec 2022Dec 2026

First Submitted

Initial submission to the registry

April 12, 2022

Completed
22 days until next milestone

First Posted

Study publicly available on registry

May 4, 2022

Completed
7 months until next milestone

Study Start

First participant enrolled

December 1, 2022

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

4.1 years

First QC Date

April 12, 2022

Last Update Submit

April 28, 2026

Conditions

Keywords

ObesityReward systemPET-scan[11C]-Raclopride

Outcome Measures

Primary Outcomes (1)

  • Change in [11C]-raclopride binding potential in the brain's reward system between study groups before and after a food challenge.

    Pre- and post-eating changes in dopamine D2 receptor availability as indexed by the \[11C\]-raclopride binding potential in the brain's reward system between subjects who underwent successful vs unsuccessful bariatric surgery

    -50 minutes (before start of PET scanning), 0 minutes (during PET break, before mixed meal), 30 minutes (after second phase of PET-scanning)

Secondary Outcomes (2)

  • The correlation between [11C]-raclopride binding potential in the brain's reward system and of questionnaires and diaries

    Pre-intervention

  • The correlation between [11C]-raclopride binding potential in the brain's reward system and of gut hormones.

    -50 minutes (before start of PET scanning), 0 minutes (during PET break, before mixed meal), 30 minutes (after second phase of PET-scanning), 60 - 90 - 120 minutes

Study Arms (2)

Unsuccessful BS (Total Weight Loss (TWL) < 20%)

EXPERIMENTAL

Fifteen who had unsuccessful BS (Total Weight Loss (TWL) \< 20%)

Other: standardized liquid mixed meal Nutridrink®

Successful BS (TWL > 25%).

EXPERIMENTAL

Fifteen who had successful BS (TWL \> 25%).

Other: standardized liquid mixed meal Nutridrink®

Interventions

Administration of food in controlled situation

Successful BS (TWL > 25%).Unsuccessful BS (Total Weight Loss (TWL) < 20%)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Bariatric surgery 24-36 months prior to the study
  • Adult (over 18y old)
  • Mentally capable to understand the consequences of the procedure and make his or her own choice without coercion
  • Able to undergo PET and MRI, according to the investigator's assessment
  • Native speaking
  • Able to participate in follow-up
  • Written informed consent

You may not qualify if:

  • Presence of a DSM-IV axis 1 disorder
  • The use of drugs that bind to dopamine D2/3 receptors, including various classes of antipsychotics and antidepressants
  • History of stroke, brain tumor, Parkinson's Disease or dementia
  • History of head trauma with loss of consciousness
  • Alcohol or substance abuse in the last 6 months
  • Alcohol consumption 24h prior to PET scanning
  • Smoking or other forms of nicotine intake 12 hours prior to PET scanning
  • Use of anorectic drugs in the last 6 months
  • Current pregnancy
  • Medication for Diabetes Mellitus
  • Claustrophobia
  • The presence of implanted metal objects of the type which may concentrate radiofrequency fields or cause tissue damage from twisting in a magnetic field (such as certain implanted devices, shrapnel, ocular metal shavings)
  • Patients with a bodyweight \> 200kg will be excluded to ensure the maximum load of the camera bed of the PET-scanner (227 kg) is not exceeded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MCL

Leeuwarden, Netherlands

Location

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 12, 2022

First Posted

May 4, 2022

Study Start

December 1, 2022

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

April 29, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations